Emerging Technologies to Achieve Oral Delivery of GLP-1 and GLP-1 Analogs for Treatment of Type 2 Diabetes Mellitus (T2DM)

Canadian Journal of Biotechnology
doi 10.24870/cjb.2017-000107
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Science Planet Inc.

Related search

Semaglutide: A New GLP‐1 Analogue for Type 2 Diabetes

Prescriber
Pharmacology
2019English

Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Dulaglutide: Third Once-Weekly GLP-1 Agonist for Type 2 Diabetes

Pharmacy Today
2014English

GLP-1 Based Therapeutics: Simultaneously Combating T2DM and Obesity

Frontiers in Neuroscience
Neuroscience
2015English

Discovery of Novel and Long Acting GLP-1 Analogs

2015English

Pdb68 - Cost-Effectiveness Analysis of Exenatide Versus GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

366. Combining Delivery of GLP-1 Gene Expressing Plasmid and DPP-4 Gene Silencing siRNA Using Chitosan-Based Nanoparticles for Type-2 Diabetes Treatment

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Patient Preferences for Frequency of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Injections in the Treatment of Type 2 Diabetes

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

The Effects of GLP-1 Analogues in Obese, Insulin-Using Type 2 Diabetes in Relation to Eating Behaviour

International Journal of Clinical Pharmacy
ToxicologyPharmacyPharmacologyPharmaceutical Science
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy